McKesson Corporation $MCK Shares Sold by Holderness Investments Co.

Holderness Investments Co. lowered its stake in shares of McKesson Corporation (NYSE:MCK) by 29.9% during the third quarter, HoldingsChannel.com reports. The firm owned 3,070 shares of the company’s stock after selling 1,308 shares during the period. Holderness Investments Co.’s holdings in McKesson were worth $2,372,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Brighton Jones LLC boosted its holdings in McKesson by 46.3% in the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after acquiring an additional 798 shares during the last quarter. Caxton Associates LLP purchased a new position in shares of McKesson in the 1st quarter worth about $233,000. Sivia Capital Partners LLC lifted its stake in shares of McKesson by 77.9% in the 2nd quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock valued at $502,000 after purchasing an additional 300 shares in the last quarter. Premier Path Wealth Partners LLC grew its holdings in shares of McKesson by 7.2% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 475 shares of the company’s stock worth $348,000 after purchasing an additional 32 shares during the period. Finally, Assetmark Inc. increased its position in McKesson by 47.4% during the 2nd quarter. Assetmark Inc. now owns 20,382 shares of the company’s stock worth $14,936,000 after purchasing an additional 6,553 shares in the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Price Performance

NYSE:MCK opened at $984.61 on Friday. The firm has a 50-day moving average of $868.77 and a two-hundred day moving average of $806.54. The stock has a market cap of $120.60 billion, a P/E ratio of 28.32, a PEG ratio of 1.59 and a beta of 0.40. McKesson Corporation has a 1-year low of $621.88 and a 1-year high of $987.37.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same period in the previous year, the company earned $8.03 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts expect that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio is presently 9.43%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on MCK shares. Wells Fargo & Company lifted their price target on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research report on Thursday, February 5th. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Robert W. Baird set a $968.00 price target on shares of McKesson in a research report on Wednesday, January 14th. Mizuho raised their price objective on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. Finally, Morgan Stanley restated an “overweight” rating and set a $966.00 price objective on shares of McKesson in a research note on Thursday, January 29th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $943.50.

Insider Activity at McKesson

In related news, Director Maria Martinez sold 349 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the sale, the director directly owned 301 shares of the company’s stock, valued at $282,900.87. This represents a 53.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares in the company, valued at $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,143 shares of company stock worth $1,046,070 over the last three months. 0.08% of the stock is owned by corporate insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.